Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients

Afonso,Julieta; Longatto-Filho,Adhemar; Da Silva,Vitor  Moreira; Amaro,Teresina; Santos,Lúcio  L.

doi:10.3892/ol.2014.2392

Phospho-mTOR in non-tumour and tumour bladder urothelium: Pattern of expression and impact on urothelial bladder cancer patients

Authors:
- Julieta Afonso
- Adhemar Longatto-Filho
- Vitor Moreira Da Silva
- Teresina Amaro
- Lúcio L. Santos
View Affiliations

Affiliations: Life and Health Sciences Research Institute (ICVS), School of Healh Sciences (ECS) University of Minho, Braga 4710-057, Portugal, Department of Urology, Portuguese Institute of Oncology (IPO), Porto 4200-072, Portugal, Experimental Pathology and Therapeutics Research Center, Portuguese Institute of Oncology (IPO), Porto 4200-072, Portugal, Department of Surgical Oncology, Portuguese Institute of Oncology (IPO), Porto 4200-072, Portugal
Published online on: July 30, 2014 https://doi.org/10.3892/ol.2014.2392
Pages: 1447-1454

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Urothelial bladder carcinoma (UBC) is heterogeneous in its pathology and clinical behaviour. Evaluation of prognostic and predictive biomarkers is necessary, in order to produce personalised treatment options. The present study used immunohistochemistry to evaluate UBC sections containing tumour and non‑tumour areas from 76 patients, for the detection of p‑mTOR, CD31 and D2‑40 (blood and lymphatic vessels identification, respectively). Of the non‑tumour and tumour sections, 36 and 20% were scored positive for p‑mTOR expression, respectively. Immunoexpression was observed in umbrella cells from non‑tumour urothelium, in all cell layers from non‑muscle‑invasive (NMI) tumours (including expression in superficial cells), and in spots of cells from muscle‑invasive (MI) tumours. Positive expression decreased from non‑tumour to tumour urothelium, and from pT1/pTis to pT3/pT4 tumours; however, the few pT3/pT4 positive cases had worse survival rates, with 5‑year disease‑free survival being significantly lower. Angiogenesis occurrence was impaired in pT3/pT4 tumours that did not express p‑mTOR. In conclusion, p‑mTOR expression in non‑tumour umbrella cells is likely a reflection of their metabolic plasticity, and extension to the inner layers of the urothelium in NMI tumours is consistent with an enhanced malignant potential. The expression in cell spots in a few MI tumours and absence of expression in the remaining tumours is intriguing and requires further research. Additional studies regarding the up- and downstream effectors of the mTOR pathway should be conducted.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Reuter VE: The pathology of bladder cancer. Urology. 67:11–17. 2006.
3	Colombel M, Soloway M, Akaza H, et al: Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol Suppl. 7:618–626. 2008.
4	Cheung G, Sahai A, Billia M, Dasgupta P and Khan MS: Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 11:132013.
5	Kaufman DS, Shipley WU and Feldman AS: Bladder cancer. Lancet. 374:239–249. 2009.
6	Shariat SF, Karakiewicz PI, Palapattu GS, et al: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 176:2414–2422; discussion 2422–2006.
7	Bellmunt J, Orsola A, Wiegel T, et al: Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 22(Suppl 6): vi45–vi49. 2011.
8	Strimpakos AS, Karapanagiotou EM, Saif MW and Syrigos KN: The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev. 35:148–159. 2009.
9	Rosner M, Hanneder M, Siegel N, et al: The mTOR pathway and its role in human genetic diseases. Mutat Res. 659:284–292. 2008.
10	Dobashi Y, Watanabe Y, Miwa C, Suzuki S and Koyama S: Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol. 4:476–495. 2011.
11	Zhou H and Huang S: Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci. 12:30–42. 2011.
12	Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 4:512011.
13	Faivre S and Raymond E: Mechanism of action of rapalogues: the antiangiogenic hypothesis. Expert Opin Investig Drugs. 17:1619–1621. 2008.
14	Dormond-Meuwly A, Roulin D, Dufour M, et al: The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors. Biochem Biophys Res Commun. 407:714–719. 2011.
15	Menon S and Manning BD: Common corruption of the mTOR signaling network in human tumors. Oncogene. 27:S43–S51. 2008.
16	Ueng SH, Chen SC, Chang YS, et al: Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int J Clin Exp Pathol. 5:806–813. 2012.
17	Leal P, García P, Sandoval A, et al: Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. Arch Pathol Lab Med. 137:552–557. 2013.
18	An JY, Kim KM, Choi MG, et al: Prognostic role of p-mTOR expression in cancer tissues and metastatic lymph nodes in pT2b gastric cancer. Int J Cancer. 126:2904–2913. 2010.
19	Rai JS, Henley MJ and Ratan HL: Mammalian target of rapamycin: a new target in prostate cancer. Urol Oncol. 28:134–138. 2010.
20	Herberger B, Puhalla H, Lehnert M, et al: Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res. 13:4795–4799. 2007.
21	Faried LS, Faried A, Kanuma T, et al: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog. 47:446–457. 2008.
22	Darb-Esfahani S, Faggad A, Noske A, et al: Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol. 135:933–941. 2009.
23	Bradshaw-Pierce EL, Pitts TM, Kulikowski G, et al: Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One. 8:e580892013.
24	Frost P, Berlanger E, Mysore V, et al: Mammalian target of rapamycin inhibitors induce tumor cell apoptosis in vivo primarily by inhibiting VEGF expression and angiogenesis. J Oncol. 2013:8970252013.
25	O’Reilly T, McSheehy PM, Wartmann M, et al: Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo. Anticancer Drugs. 22:58–78. 2011.
26	Cejka D, Preusser M, Fuereder T, et al: mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res. 28:3801–3808. 2008.
27	Fasolo A and Sessa C: Targeting mTOR pathways in human malignancies. Curr Pharm Des. 18:2766–2777. 2012.
28	Nelson V, Altman JK and Platanias LC: Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer. Expert Opin Investig Drugs. 22:715–722. 2013.
29	Gentzler RD, Altman JK and Platanias LC: An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets. 16:481–489. 2012.
30	Serrano C, Morales R, Suárez C, et al: Emerging therapies for urothelial cancer. Cancer Treat Rev. 38:311–317. 2012.
31	Hansel DE, Platt E, Orloff M, et al: Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol. 176:3062–3072. 2010.
32	Makhlin I, Zhang J, Long CJ, et al: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int. 108:E84–E90. 2011.
33	Amin MB, Srigley JR, Grignon DJ, et al: Urinary bladder cancer protocols and checklists. College of American Pathologists; Northfield, IL: 2005
34	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th Edition. Springer Verlag; New York, NY: pp. 497–506. 2010
35	Mostofi FK, Davis CJ Jr and Sesterhenn IA: Histological typing of urinary bladder tumours. World Health Organization, International Histological Classification of Tumours. 2nd Edition. Springer Verlag; New York, NY: pp. 3–30. 1999
36	Eble JN, Sauter G, Epstein JI and Sesterhenn IA: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press; Lyon: 2004
37	Afonso J, Santos LL, Amaro T, Lobo F and Longatto-Filho A: The aggressiveness of urothelial carcinoma depends to a large extent on lymphovascular invasion - the prognostic contribution of related molecular markers. Histopathology. 55:514–524. 2009.
38	Sato T, Nakashima A, Guo L, Coffman K and Tamanoi F: Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 29:2746–2752. 2010.
39	Knowles MA, Platt FM, Ross RL and Hurst CD: Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 28:305–316. 2009.
40	Polette M, Nawrocki-Raby B, Gilles C, Clavel C and Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 49:179–186. 2004.
41	Pinto-Leite R, Botelho P, Ribeiro E, Oliveira PA and Santos L: Effect of sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer Res. 28:32009.
42	Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, et al: Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomed Pharmacother. 67:116–121. 2013.
43	Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, et al: Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines. J Toxicol Environ Health A. 75:788–799. 2012.
44	Seager CM, Puzio-Kuter AM, Patel T, et al: Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2:1008–1014. 2009.
45	Seront E, Rottey S, Sautois B, et al: Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 23:2663–2670. 2012.
46	Copp J, Manning G and Hunter T: TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69:1821–1827. 2009.
47	Korkolopoulou P, Levidou G, Trigka EA, et al: A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int. 110:E1237–E1248. 2012.
48	Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology. 58:1054–1063. 2011.
49	Schultz L, Albadine R, Hicks J, et al: Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer. 116:5517–5526. 2010.
50	Park SJ, Lee TJ and Chang IH: Role of the mTOR pathway in the progression and recurrence of bladder cancer: an immunohistochemical tissue microarray study. Korean J Urol. 52:466–473. 2011.
51	Apodaca G: The uroepithelium: not just a passive barrier. Traffic. 5:117–128. 2004.
52	Khandelwal P, Abraham SN and Apodaca G: Cell biology and physiology of the uroepithelium. Am J Physiol Renal Physiol. 297:F1477–1501. 2009.
53	Gibbons JJ, Abraham RT and Yu K: Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol. 36:S3–S17. 2009.
54	Yecies JL and Manning BD: mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl). 89:221–228. 2011.
55	Yecies JL and Manning BD: Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res. 71:2815–2820. 2011.
56	Fahmy M, Mansure JJ, Brimo F, et al: Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Hum Pathol. 44:1766–1772. 2013.
57	Müller J, Ehlers A, Burkhardt L, et al: Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers. Int J Cancer. 132:1333–1340. 2013.